TG Therapeutics raises $18.1 million

TG Therapeutics Inc. (NASDAQ:TGTX) raised $18.1 million through the sale of 2.7 million shares at $6.71 in a private placement to JPMorgan Asset Management's Global Healthcare Fund. Ladenburg Thalmann underwrote the offering. TG's ublituximab ( TG-1101) is in an open-label Phase II trial to treat chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) in combination with Imbruvica ibrutinib from Pharmacyclics Inc. (NASDAQ:PCYC) and Johnson & Johnson (NYSE:JNJ). Ublituximab is a chimeric mAb against CD20. ...